52例非重型再生障碍性贫血患者环孢素A治疗2年后生活质量变化
研究纳入52例初治非重型再生障碍性贫血患者,仅用环孢素A治疗至少2年,治疗前后填写SF-36量表并与常模比较。治疗2年总有效率76.9%,心理健康得分恢复至常模水平且精力、精神健康得分高于常模,躯体健康仍低于常模。
要点
- CsA治疗2年总有效率76.9%,CR 28.8%,PR 48.1%。
- 治疗后心理健康恢复至常模,精力与精神健康得分高于常模。
- 起病时ECOG评分较低者生活质量改善更大。
核心结论
- NSAA患者生活质量低于常人,CsA治疗可改善生活质量尤其是心理健康。
- 不同社会背景患者均可从治疗中获益,起病较重者获益更大。
研究设计与样本
- 收集2014年1月至2016年1月北京协和医院门诊初治、仅用CsA至少2年的NSAA患者52例。
- 治疗前后填写SF-36量表并与正常中国人常模比较,同时评估社会背景、依从性及疗效。
主要发现
- 52例中男27例(51.9%),女25例(48.1%),中位年龄48(21~85)岁。
- 治疗2年CR 15例(28.8%),PR 25例(48.1%),NR 12例(23.1%),ORR 76.9%。
- 治疗前SF-36躯体和心理健康得分均差于常模(P<0.05)。
- 治疗后躯体方面及总体生活质量仍低于常模(P<0.05),心理健康与常模差异无统计学意义(P>0.05)。
- 精力(VT)得分58.8±20.1对52.3±20.9(P=0.023),精神健康(MH)65.9±17.6对59.7±22.9(P=0.014),均高于常模。
关键数值与推荐
- 生活质量与年龄、性别、文化程度、家庭年收入、付费方式、依从性及输血依赖均无显著相关性。
- 起病时ECOG评分较低者生活质量改善更大。
- CR和PR患者生活质量均显著改善。
临床怎么用
- 对NSAA患者启动CsA治疗时可将生活质量改善作为疗效评估维度之一。
- 治疗前ECOG评分较低者可能获得更大的生活质量获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objectives: To explore changes in the quality of life(QoL)in patients with non-severe aplastic anemia(NSAA)after 2 years of cyclosporine A(CsA)therapy, and possible factors may affect the QoL. Methods: Patients with de novo NSAA from January 2014 to 2016 who had been treated with only CsA for at least 2 years in the outpatient department of Peking Union Medical College Hospital were instructed to fill-in the SF-36 form before and after 2 years of CsA treatment. Data from NSAA were compared with those of normal controls; patients' information such as age, sex, education, annual income, type of payment, and compliance were collected, disease severity and response to treatment were also evaluated. Results: A total of 52 patients were included in our study with 27(51.9%)men and 25(48.1%)women, with the medium age of 48(21-85)years. After 2 years of treatment, 15(28.8%)patients achieved complete response(CR), 25(48.1%)achieved partial response(PR), and 12(23.1%)patients had no response(NR). The overall response rate(ORR)was 76.9%. Before the therapy, SF-36 scores in patients with NSAA were significantly lower than that of normal controls either in physical or mental component summaries(P<0.05). However, after 2 years of therapy, patients with NSAA had significant improvement of mental component summaries and recovered to normal with even higher scores in mental health(MH)(65.9±17.6 vs 59.7±22.9, P=0.014)and energy/vitality(VT)(58.8±20.1 vs 52.3±20.9, P=0.023)compared with normal controls, although they still had comparatively lower scores in physical component summaries. No associations were found between QoL and age, sex, educational level, family income, type of payment, patient adherence, or transfusion dependency. Patients with higher ECOG (the Eastern Cooperative Oncology Group score)at the beginning experienced greater progress in QoL compared to those with lower ECOG. Both patients with CR and PR had shown significant improvement in QoL. Conclusion: Patients with NSAA had impaired QoL compared with normal patients. CsA treatment can improve the QoL, especially in mental component summaries. Patients can benefit from the treatment regardless of their social status, and patients with lower ECOG at the beginning seem to benefit more from the therapy. 目的: 研究非重型再生障碍性贫血(NSAA)患者接受环孢素A(CsA)治疗前后生活质量的变化,并分析生活质量改善的影响因素。 方法: 收集2014年1月至2016年1月在北京协和医院门诊初次治疗、仅使用CsA的NSAA患者,在治疗前和治疗2年后分别填写SF-36量表,与正常中国人模型(常模)比较;并调查评估患者的年龄、性别、文化程度、家庭年收入、付费方式、依从性、治疗前一般健康状况及治疗2年后的疗效,分析其与生活质量改善的关系。 结果: 共52例患者符合入组条件,其中男性27例(51.9%),女性25例(48.1%),中位年龄48(21~85)岁。CsA治疗2年,完全治疗反应(CR)15例(28.8%),部分治疗反应(PR)25例(48.1%),无治疗反应(NR)12例(23.1%),治疗总有效率(CR+PR)76.9%。患者治疗前SF-36量表躯体和心理健康得分差于常模(P值均<0.05)。治疗后,躯体方面及总体生活质量虽仍然低于常模(P值均<0.05),但心理健康与常模比较差异无统计学意义(P值均>0.05),精力(VT)、精神健康(MH)得分高于常模[VT:(58.8±20.1)分对(52.3±20.9)分,P=0.023;MH:(65.9±17.6)分对(59.7±22.9)分,P=0.014]。不同社会背景与生活质量改善均无显著相关性。起病时体能状况评分(ECOG评分)较低者生活质量改善更大。CsA治疗有效者生活质量均得到显著改善。 结论: NSAA患者生活质量低于常人,CsA治疗可以改善患者的生活质量,尤其是心理健康情况。不同社会背景的患者均可从治疗中获益,而起病较重者获益更大。.
引用
- Chen FF, Guo ZW, Zhang LN, et al. [The change of quality of life in 52 patients with non-severe aplastic anemia after cyclosporine A therapy]. Zhonghua Xue Ye Xue Za Zhi. 2020. PMID: 33190436. doi:10.3760/cma.j.issn.0253-2727.2020.10.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。